Lupin and Gan & Lee have an exclusive China agreement for the diabetic medication bofanglutide.

$LUPIN On Monday, December 29, the pharmaceutical company Lupin Ltd announced that it has signed an exclusive license, supply, and distribution contract for bofanglutide, a novel weekly GLP-1 receptor agonist, with Gan & Lee Pharmaceuticals, a Chinese company. The arrangement is intended to increase Lupin's market share in the obese market and boost its diabetic portfolio. Gan & Lee's bofanglutide injection is intended for adults with type 2 diabetes and helps people who are overweight or obese control their weight.